Guided Therapeutics, Inc. (GTHP)
OTCMKTS
· Delayed Price · Currency is USD
0.2300
0.00 (0.00%)
Jun 18, 2025, 3:49 PM EDT
Guided Therapeutics Revenue
Guided Therapeutics had revenue of $1,000.00 in the twelve months ending March 31, 2025, down -98.78% year-over-year. In the year 2024, Guided Therapeutics had annual revenue of $7.00K, down -92.86%.
Revenue (ttm)
1,000.00
Revenue Growth
-98.78%
P/S Ratio
18,163.40
Revenue / Employee
250.00
Employees
4
Market Cap
18.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00K | -91.00K | -92.86% |
| Dec 31, 2023 | 98.00K | 85.00K | 653.85% |
| Dec 31, 2022 | 13.00K | -68.00K | -83.95% |
| Dec 31, 2021 | 81.00K | -21.00K | -20.59% |
| Dec 31, 2020 | 102.00K | 66.00K | 183.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Silence Therapeutics | 27.70M |
Guided Therapeutics News
- 9 days ago - Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor - Business Wire
- 23 days ago - Guided Therapeutics Receives $100,000 from SMI's Investment Partners to Continue Commercialization Process of LuViva in China - Business Wire
- 6 months ago - Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables - Business Wire
- 1 year ago - Guided Therapeutics' Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results - Business Wire
- 1 year ago - Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results - Business Wire
- 1 year ago - Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval - Business Wire